A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

NCT07728383 on ClinicalTrials.gov · last registry update 2026-07-27

Recruiting now, toward 40 participants. Due to report May 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Percent body weight change from baseline. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Gila Therapeutics, Inc.
Sponsor type: Industry
Enrollment: 40
Started: 2026-06-17
Primary completion: 2027-05 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent body weight change from baseline

Conditions studied

Obesity & Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.